Trastuzumab emtansine (T-DM1), the first ADC to receive Food and Drug Administration (FDA) approval for breast cancer in 2013, has proven effective in HER2+ metastatic breast cancer (Beck et al., 2017). This evidence concerns the gene ERBB2 and breast carcinoma.